Leerink Partnrs Brokers Decrease Earnings Estimates for CLDX

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Research analysts at Leerink Partnrs cut their FY2028 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a report released on Thursday, February 27th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical company will earn $0.95 per share for the year, down from their previous estimate of $0.99. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ FY2029 earnings at $6.62 EPS.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.02. The company had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%.

A number of other equities analysts also recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. UBS Group started coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective on the stock. The Goldman Sachs Group reduced their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Friday. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $55.38.

Celldex Therapeutics Stock Down 5.9 %

NASDAQ:CLDX opened at $19.35 on Monday. The firm has a market capitalization of $1.28 billion, a P/E ratio of -7.53 and a beta of 1.60. Celldex Therapeutics has a 52 week low of $19.31 and a 52 week high of $53.18. The company has a fifty day moving average of $23.75 and a 200 day moving average of $28.80.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Polar Asset Management Partners Inc. lifted its holdings in shares of Celldex Therapeutics by 1,318.0% in the fourth quarter. Polar Asset Management Partners Inc. now owns 137,550 shares of the biopharmaceutical company’s stock worth $3,476,000 after buying an additional 127,850 shares in the last quarter. TFG Asset Management GP Ltd bought a new position in Celldex Therapeutics during the fourth quarter valued at $4,852,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Celldex Therapeutics by 13.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 116,317 shares of the biopharmaceutical company’s stock worth $2,939,000 after purchasing an additional 13,722 shares during the last quarter. Vestal Point Capital LP bought a new position in Celldex Therapeutics in the 4th quarter valued at $7,707,000. Finally, Two Sigma Investments LP purchased a new stake in Celldex Therapeutics in the fourth quarter worth $835,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.